First US Warnings On Drug Claims By Delta-8 THC Supplements Also Describe Safety Concerns
Announcement and warnings, in addition to noting firms’ violative drug and disease claims, explain differences between delta-8 THC and other hemp-derived cannabinoids intended for de-scheduling as controlled substances in 2018 farm bill.
You may also be interested in...
Will DEA Saying Synthetic THCs Are Controlled Substances Help Deliver Lawful Hemp Answer?
DEA’s explanation delta-8 THC acetate isn’t hemp, along with FDA’s hemp and cannabis policies chief saying it and other cannabis derivatives aren’t hemp, should simplify decision on lawful use of hemp in non-drug products subject to FDA’s regulatory oversight.
As Quantity Of Cannabis IND Applications Grows, US FDA Has ‘Quality Considerations’ Guidance
Research targeting botanicals generally, as well as cannabis, as potential APIs is increasing, a factor in CDER’s publication of cannabis trials guidance, the FDA’s Norman Birenbaum says in an interview.
US FDA Doubts Hemp ‘Derivatives Created From Scratch’ Belong In Lawful Use Pathway
States’ histories with legalizing cannabis aren’t good models for an hemp regulatory pathway, says FDA hemp and cannabis policy chief Norman Birenbaum. Influence from those models already seen in US with ingredients including delta-8 THC marketed as hemp as defined in federal law de-scheduling it as a controlled substance.